Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. by Teirlinck, A.C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/98063
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Longevity and Composition of Cellular Immune
Responses Following Experimental Plasmodium
falciparum Malaria Infection in Humans
Anne C. Teirlinck1., Matthew B. B. McCall1., Meta Roestenberg1, Anja Scholzen1, Rob Woestenenk2,
Quirijn de Mast3, Andre J. A. M. van der Ven3, Cornelus C. Hermsen1, Adrian J. F. Luty1", Robert W.
Sauerwein1*
1Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 2Department of Laboratory Medicine, Laboratory of
Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 3Department of General Internal Medicine, Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands
Abstract
Cellular responses to Plasmodium falciparum parasites, in particular interferon-gamma (IFNc) production, play an important
role in anti-malarial immunity. However, clinical immunity to malaria develops slowly amongst naturally exposed
populations, the dynamics of cellular responses in relation to exposure are difficult to study and data about the persistence
of such responses are controversial. Here we assess the longevity and composition of cellular immune responses following
experimental malaria infection in human volunteers. We conducted a longitudinal study of cellular immunological
responses to sporozoites (PfSpz) and asexual blood-stage (PfRBC) malaria parasites in naı¨ve human volunteers undergoing
single (n = 5) or multiple (n = 10) experimental P. falciparum infections under highly controlled conditions. IFNc and
interleukin-2 (IL-2) responses following in vitro re-stimulation were measured by flow-cytometry prior to, during and more
than one year post infection. We show that cellular responses to both PfSpz and PfRBC are induced and remain almost
undiminished up to 14 months after even a single malaria episode. Remarkably, not only ‘adaptive’ but also ‘innate’
lymphocyte subsets contribute to the increased IFNc response, including abT cells, cdT cells and NK cells. Furthermore,
results from depletion and autologous recombination experiments of lymphocyte subsets suggest that immunological
memory for PfRBC is carried within both the abT cells and cdT compartments. Indeed, the majority of cytokine producing T
lymphocytes express an CD45RO+ CD62L- effector memory (EM) phenotype both early and late post infection. Finally, we
demonstrate that malaria infection induces and maintains polyfunctional (IFNc+IL-2+) EM responses against both PfRBC and
PfSpz, previously found to be associated with protection. These data demonstrate that cellular responses can be readily
induced and are long-lived following infection with P. falciparum, with a persisting contribution by not only adaptive but
also (semi-)innate lymphocyte subsets. The implications hereof are positive for malaria vaccine development, but focus
attention on those factors potentially inhibiting such responses in the field.
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Introduction
Malaria is caused by parasites of the genus Plasmodium that are
transmitted from one human host to the next by Anopheline
mosquitoes, putting an estimated 3.3 billion of the world’s popula-
tion at risk [1]. Upon inoculation by a mosquito, sporozoites
initiate an asymptomatic infection of hepatocytes from which
blood-stage forms emerge to invade and multiply exponentially
within erythrocytes. The latter process underlies the full spectrum
of morbidity and mortality associated with clinical malaria.
Compounding this global public health burden is the fact that
first infections do not immediately induce immunity. Instead,
infants in endemic areas remain susceptible to multiple new
symptomatic infections throughout childhood and early adult-
hood, and adults frequently still harbor sub-clinical parasitemia
(reviewed in [2,3]). Both poor induction (priming) of immune
responses by the parasite and rapid attrition of such responses
have been proposed as explanations, although the validity of
both hypotheses has been brought into question (discussed in
[4,5,6]).
Direct immunological evidence from studies in humans that
support or reject these theories is limited. The commonly held
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view that immune responses to Plasmodium parasites are short-lived
following exposure, is mainly based on the short half-life of specific
antibodies (reviewed in [7]). It would appear that cellular
responses to individual antigens are also either relatively short-
lived, i.e. declining within a few years of exposure [8,9,10], or at
least unstable [11,12,13,14,15], but may persist occasionally [16].
Many field studies, however, suffer from a profound difficulty in
controlling for exposure amongst study subjects, limiting interpre-
tation thereof. Anecdotal evidence from historical malaria-therapy
studies suggests that cellular proliferative responses to crude whole
parasite antigen can be detected in donors several years after a
single infection [17]. More recently, robust cellular cytokine
responses were detected three months post infection in previously
naı¨ve volunteers [18]. Within these cellular immune responses,
interferon-gamma (IFNc) in particular is considered to play a
major role (reviewed in [19]).
Experimental human malaria infections by bites of P. falciparum
infected mosquitoes offer a controlled measure of exposure and a
safe and well-established model, and have been performed on
hundreds of volunteers over the past two decades primarily for
assessing the efficacy of candidate malaria vaccines [20]. This
model allows controlled studies on the development and
maturation of intrinsic immune responses in the course of a
malaria infection, and on how (long) cellular memory is
maintained. Here we conducted a comprehensive longitudinal
study of cellular responses, focusing on IFNc production by
multiple subsets of innate and adaptive immune cells, induced by
both P. falciparum sporozoites (PfSpz) and asexual blood-stage
parasites (P. falciparum-infected red blood cells; PfRBC) in malaria-
naı¨ve volunteers undergoing single or multiple experimental
infections with P. falciparum.
We show that even a single patent malaria episode induces
robust cellular re-call responses to both parasite stages, persisting
at almost undiminished levels at least 14 months post infection and
involving both adaptive and innate compartments.
Results
Cellular IFNc re-call responses to both sporozoites and
blood-stage parasites are readily induced and long-lived
following infection
In vitro parasite-specific responses were measured in peripheral
blood mononuclear cells (PBMC) isolated from two sets of human
volunteers prior to and at several time points after exposure to P.
falciparum infection. Group A volunteers (n = 10) were exposed
thrice to immunizing bites (I) of infected mosquitoes whilst under
chloroquine prophylaxis and thereafter challenged (C) once again;
Group B volunteers (n = 5) received only a single infection in
parallel with Group A challenge (Figure 1). Total lymphocyte
responses to PfSpz and PfRBC were barely detectable above
background prior to exposure (day I-1) in both groups of
volunteers (Figure 2). Re-call responses by lymphocytes to both
PfSpz and PfRBC, as measured by IFNc production following
overnight re-stimulation, were detectable in Group A volunteers
following exposure to immunizing bites (day C-1 compared to I-1,
one-way ANOVA with Dunnet’s post-test, p,0.05 for PfSpz and
p,0.01 for PfRBC) and remained high after re-challenge until day
C+35 (p,0.001 and p,0.01, respectively) (Figure 2.A+C). Of
note, one volunteer displayed a disproportionally amplified IFNc
response to PfRBC at time point C+35. For this reason, this
volunteer was left out of statistical analysis as an extreme outlier.
Re-call responses to PfRBC (p,0.001, I-1 compared to C+35),
and to a lesser extent also to PfSpz, became detectable in Group B
volunteers following their first infection (Figure 2.B+D). This
shows that cellular immune responses to whole parasites are
readily inducible in previously-naı¨ve human volunteers, following
a small number of, or even a single P. falciparum infection. Most
remarkably, in further experiments with samples collected at later
time points (days C+140 and C+400), we found that parasite-
specific cellular responses did not wane after exposure. Instead,
they remained robust more than a year post-challenge, albeit with
considerable inter-individual variation (Figure 2).
Cellular responses to protein pools of either sporozoite-stage
(CSP and TRAP), liver-stage (LSA-1 or Exp-1) or blood-stage
(AMA-1, MSP-2, MSP-3 and GLURP) antigens (all leading
malaria vaccine candidates), however, were never detectable
above background.
abT and cdT cells are the main in vitro IFNc-producers in
response to PfRBC following infection
Many different lymphocyte subsets, including abT cells, cdT
cells and NK cells, have variously been shown capable of respond-
ing to PfRBC. Therefore, we assessed IFNc responses by those cell
types to PfRBC prior to (I-1 for Group A, I-1 and C-1 for Group
B) and post exposure (C-1 and later for Group A, C+9 and later
for Group B; flow cytometry gating strategy illustrated in Figure
S1). Relative proportions of lymphocyte subsets within the total
peripheral population did not differ markedly over time at the
various time points assessed (Table S1). The only exception were
cdT cells, the relative numbers of which increased within the
peripheral lymphocyte population post exposure in both sets
of volunteers (p = 0.0013 for Group A; p = 0.029 for Group B,
one-way ANOVA, I-1 to C+35). Response patterns in most
lymphocyte subsets, including abT cells, NKT cells and NK cells,
mirrored the dynamics of the total lymphocyte response in relation
to exposure: whereas almost no responses above background could
be detected in volunteers at inclusion, IFNc responses to PfRBC
became clearly detectable following challenge (Figure S2). In
contrast, a large proportion of cdT cells (median 7.9% and 6.8%
for Group A and B, respectively) demonstrated the capacity to
Author Summary
A decade into the 21st century, malaria remains respon-
sible for an intolerable global health burden and an
effective vaccine is sorely needed. Compounding the many
technical hurdles in developing such a vaccine, (naturally-
acquired) immunity to malaria is generally perceived to be
short-lived, although direct evidence from field studies is
conflicting. To overcome this issue, we measured the
development of immune responses against the malaria
parasite Plasmodium falciparum in human volunteers
undergoing experimental malaria infections for the first
time, allowing a uniquely detailed analysis thereof. We
found that cellular immune responses against two
clinically-relevant life-stages of the parasite are not only
rapidly acquired following even a single malaria infection,
but also remain virtually undiminished over a year later –
an unprecedented measurement. These findings refute
conclusively the notion that an intrinsic defect exists in
either the development or persistence of cellular immune
responses against malaria. This realization, in conjunction
with a growing recognition that such responses are indeed
associated with clinical protection against malaria, mark-
edly enhances the prospect of one day developing a
successful vaccine. Simultaneously, however, these results
re-focus attention on the question of why the develop-
ment of long-lived immune responses is often inhibited
under conditions of natural exposure.
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Figure 1. Flowchart of Experimental Human Malaria Infection study. Black and white mosquito symbols indicate exposure to infected
mosquito bites and uninfected mosquito bites, respectively. Development of patent blood-stage parasitemia following the first three inoculations
was prevented by prophylactic chloroquine treatment, indicated by grey shading. Arrow heads indicate time points of immunological assessment:
prior to immunization (I-1), prior to patent challenge (C-1), during expected blood-stage infection (C+9), two weeks after treatment (day C+35), 4.5
months post-challenge (day C+140) and again 1.1 year post-challenge (day C+400).
doi:10.1371/journal.ppat.1002389.g001
Figure 2. Induction and persistence of IFNc responses to Pf RBC and Pf Spz during experimental malaria infection. PBMC were isolated
from volunteers prior to inclusion (day I-1), immediately prior to patent challenge (day C-1), during expected blood-stage malaria infection (day C+9),
two weeks after treatment (day C+35), 4.5 months post-challenge (day C+140) and again 1.1 year post-challenge (day C+400). Note that Group A, but
not Group B volunteers were exposed thrice to immunizing sub-patent infections between day I-1 and C-1 (Figure 1). PBMC of volunteers of Group
A (A+C) and Group B (B+D) were stimulated in vitro for 24 hours with PfRBC (A+B) or PfSpz (C+D) or their respective uninfected red blood cells
(uRBC) or salivary glands from uninfected mosquitoes (MSG) controls, then stained for intracellular IFNc and analyzed by flow cytometry. Shown are
the percentage of total lymphocytes staining positive for IFNc at each time point. Background responses were subtracted from the responses to
parasite stimuli for every individual volunteer at every individual time point. Symbols represents responses by individual Group A volunteers (n = 10)
and Group B volunteers (n = 5) for whom sufficient cells were available. Horizontal lines represent group medians. Median background values for
uRBC were 0.01% [0.01–0.03] (median [IQR]) on I-1 up to C+35 and 0.03% [0.01–0.16] on C+140 and C+400. Background values for MSG were 0.02%
[0.01–0.02] on I-1 up to C+35 and 0.07% [0.03–0.25] on C+140 and C+400.
doi:10.1371/journal.ppat.1002389.g002
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respond to PfRBC even prior to exposure. Following infection, this
percentage increased still further (p = 0.013 Group A; p = 0.003
Group B, one-way ANOVA I-1 to C+35). Responses in ‘cdNKT’
cells, relatively infrequent in total number, resembled this pattern
of regular cdT cells (Table S1 and Figure S2).
Next, we assessed the relative contribution of the different
lymphocyte subsets to the total IFNc response at various time
points during the study (Figure 3) in volunteers of Group A. Few
lymphocytes produced IFNc in response to PfRBC prior to
exposure (I-1), of which 63% (median) were cdT cells and 15%
abT cells, with cdNKT cells (11%) and NK cells (1.9%) making up
most of the remainder. Interestingly, despite an increase in the
overall proportion of responding cells over time, the relative
contributions of the various lymphocyte subsets remained more or
less stable following repeated exposure (C+35) (57%, 22%, 6.7%
and 4.1%, respectively). By day 400 post-challenge, the dominat-
ing cell subsets contributing to overall IFNc production remained
abT and cdT cells (35%, 25%, 11% and 17%, respectively). The
contribution of the various cell subsets to responses in Group B
volunteers also remained comparable over time (data not shown).
Thus, not only ‘adaptive’ abT cells and ‘semi-innate’ cdT cells,
but clearly also ‘innate’ NK and NKT cells contributed to the
overall increase in lymphocytes responding to P. falciparum by IFNc
production following exposure (Figure 3).
A more in depth phenotypic analysis of responding T cell subsets
in donors with sufficient responses at the latest time point (C+400,
Figure S3) revealed that IFNc-producing CD4+ T cells markedly
outnumbered CD8+ T cells in response to both sporozoite and
blood-stage parasites post-challenge. Following in vitro re-stimulation
with PfRBC, 16% [13–22] (median [IQR]) and 26% [20–32] of
IFNc-producing T cells were of the CD4+CD8- T-helper phenotype
in Group A and B volunteers, respectively. In contrast, only 4.5%
[3.1–5.6] and 7.3% [4.7–8.8] were CD4-CD8+ cytotoxic T
lymphocytes (CTLs). The majority of IFNc-producing T cells in
response to PfRBC, however, were CD4-CD8- cells. Analysis in a
subset of donors showed that these cells were predominantly cdT
cells (data not shown). The contribution of CD4+ T cells was even
more pronounced for PfSpz-induced responses, with 70% [65–75]
of IFNc+ T cells belonging to the CD4+CD8- population in Group
A volunteers, and only 1.7% [0.9–2.5] to the CD4-CD8+ population
(day C+400, Figure S3). Thus, whereas both CD4-CD8- T cells
and CD4+ T cells dominated responses to PfRBC, the IFNc
response to PfSpz was primarily mediated by CD4+ T cells only.
Cells showing in vitro parasite-specific IFNc re-call
responses predominantly display an effector memory
phenotype both early and late after infection
Early after treatment (day C+35) in Group A volunteers, 84%
[80–87] (median [IQR]) and 0.1% [0.0–0.4] of IFNc-producing
lymphocytes displayed effector memory (EM, CD45RO+CD62L-)
and central memory (CM, CD45RO+CD62L+) phenotypes, respec-
tively, following 24-hour in vitro PfRBC re-stimulation. Remarkably,
despite an overall increase in the response to PfRBC in Group A
volunteers on day C+400, the relative contributions of CD62L- EM
and CD62L+ CM cells remained largely stable: 72% [67–75] and
0.6% [0.6–0.8], respectively (Figure 4.A). Corresponding values for
Group B volunteers at day C+35 were 76% [74–79] and 0.5% [0.3–
1.1] and remained constant over time, both in terms of percentage of
responding cells and in EM/CM distribution (Figure 4.B).
Responses to PfSpz stimulation showed an EM/CM pattern very
similar to PfRBC responses as determined for group A volunteers
(Figure 4.C). cdT cells also displayed an EM phenotype
(CD45RO+CD62L- or CD62Lintermediate) as shown in Figure
S1.C. Thus, in vitro parasite-specific re-call responses were primarily
found in EM-type populations, which include both abT cells and
cdT cells, even months after infection. Cells of CD62L+ CM
phenotype, in contrast, were detectable in only a negligible fraction
of the total re-call response at all time points examined.
Immunological memory for PfRBC appears to be carried
within both the abT cell and cdT cell compartments
Since both abT cells and cdT cells display memory phenotypes
and can mount adaptive responses, we assessed their respective
ability to initiate cellular re-call responses to PfRBC. To this end, we
separated and re-combined cdT cells and other PBMC (consisting
of approximately 80% abT cells and 5% NK cells) from both
inclusion (I; ‘Pf-naı¨ve’) and 35 or 140 days post-challenge (C; ‘Pf-
experienced’) of volunteers from both groups for whom sufficient
cells were available (Figure 5.A). Following in vitro stimulation, total
numbers of IFNc+ lymphocytes in naı¨ve PBMC populations
supplemented with Pf-experienced cdT cells were significantly
higher than in populations containing only Pf-naı¨ve cells (I-I versus
I-C; p,0.05, One-way ANOVA). This suggests that the cdT
compartment carries some immunological memory for PfRBC
(Figure 5.B). Indeed, the PfRBC response by Pf-experienced cdT
cells in some donors was more than twice as high compared to that
by Pf-naı¨ve cdT cells, even in the presence of otherwise naı¨ve
PBMC populations (data not shown). IFNc responses in PBMC
populations containing Pf-experienced cdT-depleted cells (mainly
abT cells) also appeared higher than in populations containing only
Pf-naı¨ve cells (I-I versus C-I; not significant).
Long-lived polyfunctional memory re-call responses to
malaria parasites are more prominent in anti-PfSpz
compared to anti-PfRBC responses
Whereas IFNc has many direct effector functions, IL-2 is
important for T cell proliferation and induction of cellular
Figure 3. Contribution of innate, semi-innate and adaptive
lymphocyte subsets to the total IFNc+ response to Pf RBC. PBMC
isolated from Group A volunteers at the respective study time points
were stimulated with PfRBC or uRBC and stained for intracellular IFNc and
surface expression of CD3, cdT and CD56 (gating strategy shown in
Figure S1.A). Pie charts show the relative contributions of abT cells
(CD3+cd-CD56-), cdT cells (CD3+cd+CD56-), NK cells (CD3-cd-CD56+), NKT
cells (CD3+cd-CD56+), ‘cdNKT’ cells (CD3+cd+CD56+) and other lympho-
cytes to the total number of IFNc+ cells responding to PfRBC (corrected
for uRBC background). Shown are median values for ten Group A
volunteers; pie chart surface areas directly correlate with the magnitude
of (total) IFNc+ responses. At time point I-1 themedian [IQR] contribution
of cdT cells, cdNKT cells, abT cells & NK cells to total IFNc responses was
63% [45–74], 11% [6.4–15], 15% [5.1–37] & 1.9% [0.3–5.6], respectively; at
C+35 57%[ 47–59], 6.7% [4.0–8.9], 22% [17–28] and 4.1% [3.0–7.1] and
C+400 35% [29–44], 11% [8.0–16], 25% [20–28] & 17% [12–25].
doi:10.1371/journal.ppat.1002389.g003
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memory responses. In a final set of experiments, we therefore
explored the dynamics of EM lymphocytes producing either IL-2
or IFNc alone (unifunctional), or both cytokines simultaneously
(polyfunctional cells), in response to PfRBC and PfSpz. In Group A
volunteers, the percentage of total IL-2+ EM cells responding to
PfRBC, although low in absolute numbers, increased significantly
from 0.08% [0.04–0.12] (median [IQR]) of EM cells at day I-1, to
0.31% [0.17–0.45] at day C-1 (p,0.001, one-way ANOVA with
Dunnett’s post-test) and 0.22% [0.19–0.42] at day C+35 (p,0.01,
Figure S4.A) and remained clearly detectable at day C+140 and
day C+400. This was in line with the increase in total lymphocyte
IFNc responses to PfRBC after immunization (Figure 2).
Similarly to both total IFNc and total IL-2 responses, the
percentage of EM-type cells producing both IFNc and IL-2 in
response to PfRBC increased from 0.025% [0.003–0.078] on day
I-1 to 0.14% [0.09–0.22] on C-1 (p,0.01) and 0.13% [0.10–0.18]
on day C+35 (p,0.01, Figure S4.B) and remained present up to
day C+400. The relative contribution of such polyfunctional cells
to the overall number of cytokine producing EM cells, however,
remained relatively stable with an apparent slight, but non-
significant increase on day C-1 and C+9 (Figure S5).
Total IL-2 and polyfunctional responses to PfSpz by EM cells
from Group A volunteers remained low up to C+35 (p = 0.8 and
0.1, respectively, compared to I-1). IL-2 increased from C+140 to
C+400 (p = 0.039, paired Student’s t-test; Figure S4.A). A similar
trend was seen for polyfunctional responses (p = 0.15; Figure
S4.B). Interestingly, months after malaria infection, the contribu-
tion of IFNc+IL-2+ EM cells to the total EM cytokine response
towards PfSpz was relatively more pronounced than to that against
PfRBC. Specifically, on day C+140 and C+400 the relative
contribution of polyfunctional EM cells was 37% [25–62] and
19.2% [16–30] in response to PfSpz, compared to 3.3% [1.5–4.3]
and 3.4% [2.0–5.3] in response to PfRBC (p,0.001 and p,0.05
respectively; two-way ANOVA with Bonferroni post-test; data not
shown and Figure 6). Thus, although infrequent in total number,
polyfunctional EM cells with specificity for both PfRBC and PfSpz
were readily induced upon exposure, and formed a greater relative
contribution to PfSpz than to PfRBC responses.
Discussion
In this study we delineate the dynamics and composition of
cellular immune responses to both sporozoites and asexual blood-
stage Plasmodium falciparum parasites following infection in previ-
ously-naı¨ve individuals. We demonstrate unequivocally that
specific IFNc responses to both stages of the malaria parasite are
not only readily induced following infection, but also persist more
or less undiminished over at least 14 months in the absence of
further exposure. The main contributors to these whole parasite-
specific IFNc responses are cdT cells and CD4+ EM T cells, with
NK cells making up a smaller remaining fraction of responding
cells. We show that not only adaptive, but also semi-innate and
innate lymphocytes responses exhibit an immunological re-call
pattern and present evidence suggesting that immunological
Figure 5. Immunological memory carriage by the cdT compartment vs other PBMC. (A) Cryopreserved PBMC isolated from volunteers at
inclusion (I) or 35 or 140 days post-challenge (C), were thawed and separated by magnetic beads into cdT+ lymphocytes (white) and remaining cdT-
PBMC (shades of grey, e.g. abT cells, NK cells, B cells, monocytes). Following autologous re-combination at original ratios, PBMC were stimulated,
stained and measured as for Figure 3. (B) Shown are percentages of total lymphocytes staining IFNc+ following incubation with PfRBC (corrected for
uRBC background). Data represent median+IQR of seven volunteers from whom sufficient cells were available for the assay.
doi:10.1371/journal.ppat.1002389.g005
Figure 4. Contribution of EM and CM cells to the total IFNc response to Pf RBC and Pf Spz. PBMC isolated from volunteers at various study
time points were stimulated in vitro for 24 hours with PfRBC (A+B) or PfSpz (C) and stained for the memory marker CD45RO and the homing marker
CD62L. Bars show the contributions of effector memory (EM, CD45RO+CD62L-), central memory (CM, CD45RO+CD62L+) and naive lymphocytes
(CD45RO-) to the total percentage of IFNc-producing cells over time. Height of bars represents median values for Group A (A+C) and Group B (B)
volunteers for the different cell subsets. Donors with insufficient numbers of IFNc responding cells to assess the relative contribution of cell subsets
were excluded from this composition analysis. Numbers below the bars represent the number of donors included per time point. ND – not done:
insufficient numbers to reliably assess group medians; this was similarly the case for anti-PfSpz responses in group B. Since only donors with sufficient
numbers of responding cells to assess the relative contribution of lymphocyte subsets are represented, these distributions may appear biased
towards patterns in relatively stronger responders.
doi:10.1371/journal.ppat.1002389.g004
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memory for PfRBC is carried within both the abT cell and cdT
cell compartments.
Our demonstration of lengthy persistence of cellular immuno-
logical responses following P. falciparum infection in humans stands
in contrast to the popularly held perception that clinical immunity
to malaria is short-lived. As discussed previously by Struik et al. [6]
studies reporting such short-lived immunity are mainly anecdotal
and few consistent data pro or contra this hypothesis have been
published. Our current findings prove that long-lived cellular
responses can be adequately maintained, at least when induced
under experimental conditions.
A central mediator of such cellular immunological responses to
the malaria parasite is the cytokine IFNc (reviewed in [19]). In vitro
parasite-specific IFNc responses have been shown by us and others
to associate with protection against malaria both amongst volun-
teers undergoing experimentally induced infection [21,22,23] and
naturally-exposed human populations [24,25,26,27]. Phenotypic
characterization of the in vitro IFNc response to whole blood-stage
parasites (PfRBC) in malaria-naive donors has variously implicated
‘innate’ natural killer (NK) cells [28,29,30], ‘semi-innate’ cdT cells
[31,32] (including NK-like cdT cells [33]) and ‘adaptive’ abT cells
[32,34,35]. It remains unknown, however, how these intrinsic
responses develop and mature in the course of a malaria infection
and how (long) cellular memory is maintained.
Consistent with findings by others [31,33], we show that ‘semi-
innate’ cdT cells comprise the largest population of lymphocytes
responding with IFNc production to PfRBC in malaria-naı¨ve
donors. Interestingly, this remains largely true following exposure,
despite the obvious increase in ‘adaptive’ responses. Two factors
may contribute to the overall increase in responding cdT cell
numbers: i) The overall proportion of cdT cells in the PBMC pool
increases following exposure to parasites, which persists for at least
a year. A transient dip in circulating cdT cells during infection,
followed by reactive increase afterwards, has been observed before
in primary [36,37] but not in repeated malaria infections [38]. ii) A
slightly increased proportion of these cdT cells responds to PfRBC
following infection. This increase may represent the recruitment of
PfRBC-specific cdT clones to the peripheral circulation or a non-
specific bystander effect, since cdT cells can readily respond to P.
falciparum lysate by proliferation in a polyclonal fashion [39,40].
Whatever the underlying mechanism, our data suggest that the cdT
compartment does contribute autonomously to cellular immuno-
logical memory up to 14 months post infection, independently of
other PBMC including abT cells. In contrast, we and others have
recently shown that the ‘re-call-like’ response observed in NK cells
post infection is in fact fully dependent on abT cells [30,41]. These
data can be combined into a model in which ‘semi-innate’ cdT cells,
‘adaptive’ abT cells and ‘innate’ NK cells all contribute to a robust
and long-lived IFNc response following infection with P. falciparum,
although through different mechanisms. For cdT cells this is largely
through an overall expansion of this compartment in peripheral
blood, in addition to a minor increase in the proportion of
responding cdT cells. For abT cells the proportional increase in
response is also relatively small, but in absolute terms these
lymphocytes already make up the vast majority of PBMC
populations. NK cells finally, although fewer in absolute terms,
show a much larger proportional increase in response, albeit
dependent on the increase in T cell responses [30].
The majority of responding T cells displays an EM (CD45RO+
CD62L-) phenotype, even over a year post infection, at least in
donors with sufficient numbers of responding cells to assess this.
Whether such a composition is also representative of extremely
low responders, or whether those donors exhibit a relative
response deficit in a particular lymphocyte sub-set, cannot as yet
be determined.
The apparent scarcity of responding CD62L+ CM cells may be
partly due to the fact that CM cells by definition form only a minor
population within the peripheral blood, residing primarily in
‘target’ tissues (e.g., skin and liver) and lymph nodes. Another
possibility is that this pattern is inherent to short-term in vitro assays
such as ours where within the short timeframe of 24 hours, effector
memory cells, which are defined by their ability to perform
immediate (cytokine producing) effector function, will preferen-
tially respond. Finally, the low number of CD62L expressing
responding lymphocytes could be due to loss of CD62L
expression, since following antigenic stimulation CM cells can
differentiate into an effector memory phenotype and subsequently
acquire effector function [42,43]. Thus the formal compartmental
origin of responding cells cannot be determined with certainty
from this assay.
Figure 6. Uni- and polyfunctional EM T cell responses to Pf RBC and Pf Spz one year post-infection. Data represent percentage of
effector memory (EM) cells producing either IFNc alone, IFNc and IL-2, or IL-2 alone, following 24 hours in vitro stimulation with (A) PfRBC or (B) PfSpz
at 400 days after challenge (C+400) for seven individual volunteers of Group A.
doi:10.1371/journal.ppat.1002389.g006
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The importance of polyfunctional lymphocytes in immunolog-
ical protection is believed to depend on i) their higher cytokine
production [23] and hence more potent effector capability
compared to monofunctional cells [44] and ii) their role in the
induction and persistence of T cell memory [45]. We recently
showed that the development of protection against infection with
P. falciparum in human volunteers is associated with the induction
of IFNc+IL-2+ double-positive (polyfunctional) EM T cells in
response to PfRBC [22,23]. Despite an overall increase in the
number of responding lymphocytes up to one year post infection,
we show here that the relative contribution of polyfunctional cells
to the total response remains roughly constant. This may indicate
that little differentiation takes place in the functionality of cellular
immune responses to PfRBC following exposure [46]. It will be of
obvious interest to explore this further in future studies and to
determine whether such responses genuinely afford protection.
In contrast to responses to the asexual stage of the malaria
parasite, sporozoite-specific cytokine responses have received little
attention to date. We find that similar to PfRBC responses, IFNc
responses to PfSpz are readily induced and persist following
exposure to infected mosquito bites. Furthermore, as for PfRBC
responses, IFNc production dominates the total cytokine response.
A striking feature of the anti-PfSpz response, however, is that
polyfunctional IFNc+/IL-2+ cells form a relatively larger compo-
nent of this compared to PfRBC. Whether this represents a
genuine acquisition of effector function of the anti-PfSpz response
or conversely a failure of these lymphocytes to terminally
differentiate into IFNc single producers [46] remains to be
determined.
Our data demonstrate that there is no intrinsic deficit in either
the induction or persistence of cellular responses to P. falciparum
after experimental infection. This raises the obvious question as to
why clinical immunity to malaria develops so slowly amongst
naturally exposed populations [2,4]. More specifically, why do
cellular responses to P. falciparum antigens in naturally exposed
donors appear to be so transient/unstable [8,10,11,12,13,14,15]
and tend in fact to be lower than in non-exposed donors [47,48]?
Several lines of reasoning may help to explain this paradox.
Firstly, by the time treatment is sought by and initiated in
patients in resource-poor endemic settings, their parasitemia is
typically higher compared to that in our strictly-observed
volunteers. High parasitemia has been shown to inhibit the
development of immunity both in mice [49] and in humans [11].
This may be due to active suppression or elimination of
responding T cells [50,51] by P. falciparum, resulting in reduced
Pf-specific cellular responses following repeated or chronic
infection [11,47,48,52]. Obvious accomplices are regulatory T
cells [53,54,55,56], and a comparison of the dynamics of
regulatory T cells in natural and experimental infections would
be informative in this regard. Secondly, underlying differences in
the status of the immune system of inhabitants of the rural tropics
may predispose to tolerant, as opposed to sterilizing, immune
responses [57]. This may be due to e.g. malnutrition [58] or
helminth co-infections [59,60]. Another factor may be the
inherent immaturity in the immune systems of infants and young
children, the stage in life at which malaria infections are typically
first experienced in endemic settings [61,62], as well as prior in
utero exposure [63]. Indeed, IFNc responses to P. falciparum
antigens in children tend to be weaker than in adults
[14,64,65,66,67], although of course the effect of prior exposure
in these studies cannot be distinguished from that of age per se´. In
addition, immunization and in vitro PBMC re-stimulation in our
experimental infection model were performed with homologous
strain parasites, whereas in field studies prior strain exposure
varies. Well-described target antigens for protective immunity
exhibit high rates of genetic variation, hindering cross-protective
immunity in the field [68]. Finally, the immune modulating effects
of chloroquine might have enhanced the development of immune
responses during the immunization process [69], possibly
contributing to the persisting immune responses in Group A.
Despite these caveats in extrapolating our findings to the
situation in endemic areas, we show that robust long-lasting
cellular immune responses to malaria parasites can be readily
induced under experimental conditions, and extend our under-
standing of how cellular immunological memory to P. falciparum
develops and is maintained following exposure.
Materials and Methods
Parasites
NF54 strain P. falciparum asexual blood-stage parasites, regularly
screened for mycoplasma contamination, were grown in RPMI-
1640 medium containing 10% human A+ serum at 5% hematocrit
in a semi-automated suspension culture system, in the absence of
antibiotics and in an atmosphere containing 3% CO2 and 4% O2.
For in vitro stimulation experiments, asynchronous asexual-stage
cultures of NF54 strain parasites were harvested at a parasitemia of
approximately 5–10% and mature asexual stages purified by
centrifugation on a 27% and 63% Percoll density gradient [70].
This purification step results in preparations of 80-90% parasit-
emia, consisting of more than 95% schizonts/mature trophozoites.
Preparations of parasitized red blood cells (PfRBC) were washed
twice in PBS and cryopreserved at 150x106/ml in 15% glycerol/
PBS in aliquots for use in individual stimulation assays.
Cryopreserved PfRBC form almost as strong a stimulus as
freshly-prepared PfRBC and have identical stimulatory character-
istics (Figure S6). Their use in large experiments has logistical
advantages, in addition to reducing confounding influences due to
inter-batch variation. Mock-cultured uninfected erythrocytes
(uRBC) were obtained similarly and served as controls.
Sporozoites were obtained from Anopheles stephensi mosquitoes
that were reared according to standard procedures in our
insectary. Infected mosquitoes were obtained by feeding on
gametocyte-containing cultures of NF54 strain P. falciparum, as
described previously [71]. On day 21–28 after infection, the
salivary glands of the mosquitoes were collected by hand-
dissection. Salivary glands were collected in RPMI-1640 medium
(Gibco) and homogenized in a custom glass grinder. Sporozoites
were counted in a Bu¨rker-Tu¨rk counting chamber using phase-
contrast microscopy. Sporozoites were cryopreserved at 166106/
ml in 15% glycerol/PBS in aliquots for use in individual
stimulation assays. Sporozoites that had undergone one freeze-
thaw cycle were determined microscopically to be still intact, but
were no longer able to glide (assay described in [72]). To control
for a possible immune-stimulatory effect of salivary gland
remnants in the sporozoite preparation, salivary glands from an
equal number of uninfected mosquitoes (MSG) were obtained
similarly and served as a background control.
Human ethics statement
All volunteers were recruited after giving written informed
consent. The study was approved by the Institutional Review
Board of the Radboud University Nijmegen Medical Centre
(CMO 2006/207).
Human infections
The basic design and outcome of experimental human malaria
infections at our centre has been described before [73]. For the
Persistence of Cellular Memory to Malaria
PLoS Pathogens | www.plospathogens.org 8 December 2011 | Volume 7 | Issue 12 | e1002389
study presented here [23], 15 healthy malaria naı¨ve Dutch
volunteers were recruited and randomized double-blind to either
Group A (n = 10) or Group B (n = 5). Group A volunteers were
immunized by exposure on three occasions, at monthly intervals,
to the bites of 12-15 NF54 strain P. falciparum-infected mosquitoes,
whilst continuously taking a standard prophylactic regimen of
chloroquine (300mg base per week). Group B volunteers similarly
took chloroquine and were exposed to the same number of bites,
but from uninfected mosquitoes. Two months after the final
exposure and one month after discontinuation of chloroquine
prophylaxis, all 15 volunteers were challenged by exposure to the
bites of 5 P. falciparum-infected mosquitoes and followed-up closely
for symptoms and signs of malaria. As soon as they were found to
be thick blood-smear positive, volunteers were treated with a
standard curative regimen of artemether/lumefantrine (AL)
consisting of six doses of 13 80/480 mg over three days. Duration
and peak height of parasitemia in volunteers following each round
of infection, as measured retrospectively by PCR [23], is shown in
Table S2.
Cellular immunology
Venous whole blood was collected into citrated CPT vacutai-
ners (Becton and Dickinson, Basel) at inclusion (day I-1), and
immediately prior to challenge (day C-1), during expected blood-
stage malaria infection (day C+9), two weeks after treatment with
AL (day C+35) and again 4.5 months (day C+140) and 1.1 year
(day C+400) after challenge (Figure 1). Peripheral Blood
Mononuclear Cells (PBMC) were obtained by density gradient
centrifugation, washed three times in cold PBS, enumerated,
frozen down in fetal-calf serum containing 10% dimethylsulfoxide
and stored in liquid nitrogen. Immediately prior to use, cells were
thawed, washed twice in RPMI and re-suspended in complete
culture medium (RPMI 1640 Dutch modification (Gibco)
containing 2 mM glutamine, 1mM pyruvate, 50 mg/ml gentamy-
cine and 10% human A+ serum, (Sanquin, Nijmegen)) for a final
concentration of 2.56106/ml. PBMC were transferred into 96-
well round-bottom plates and stimulated in duplicate wells with
either 5x106/ml (final concentration) cryopreserved PfRBC or
uRBC, or 5.66105/ml cryopreserved sporozoites or the extract of
an equivalent number of uninfected mosquito salivary glands in a
total volume of 200 ml/well for 24 hours at 37uC/5%CO2. Dose
and duration of stimulation were chosen based on earlier
optimization assays. Initial experiments included samples from
time points I-1 through C+35; in a later set of experiments, time
points C+140 and C+400 were compared. In a subset of
experiments, PBMC from time points I-1 through C+35 were
instead stimulated with protein pools of individual purified
sprorozoite-stage (CSP and TRAP), liver-stage (LSA-1 or Exp-1)
or blood-stage (AMA-1, MSP-2, MSP-3 and GLURP) antigens in
concentrations of both 5 and 30 mg/ml per antigen. Full length
CSP [74] was kindly provided by A. Birkett, TRAP MR149A,
MSP-2 MR141 [75], PfExp-1 MR95 [76] by G. Corradin, MSP-3
[77] by C. Oeuvray, GLURP [78] by M. Theisen, LSA-1 [79] by
T. Richie and AMA-1 [80] by A. Thomas. In these latter
experiments 60 IU human recombinant IL-2 (Proleukin, Novartis)
was added to the culture medium for optimal cellular responses. In
all experiments, 100mL/well supernatant was removed 4 hours
prior to cell harvest and replaced with 100mL/well fresh culture
medium containing Brefeldin A (Sigma) with a final concentration
of 10mg/ml.
Depletion/recombination
For recombination experiments, PBMC collected at inclusion (I)
and post-challenge (C) from seven donors from Group A and B for
whom sufficient cells were available, were divided into two
aliquots. For two of these donors, cells from day 35 post-challenge
were used and for the other five donors C+140 cells. One aliquot
of each sample was depleted of cdT cells by magnetic beads,
whereas untouched cdT+ cells were isolated from the second
aliquot by negative selection (Anti-TCR c/d MicroBead Kit and
TCRc/d+T Cell Isolation Kit, respectively, both from Miltenyi
Biotech), according to the manufacturer’s instructions. Following
separation, autologous I/C cdT- and cdT+ cells were recombined
at their original ratios. Purity of depletion was consistently .90%,
whereas purity of negative selected untouched cdT+ cells varied
between 40–80%. The majority of contaminating non-cdT cells in
these negatively selected populations consisted of NK and other
non-T lymphocytes. Since the proportion of cdT+ cells added
directly reflected the proportion of these cells in the PBMC
population (I or C) from which they were derived (see also Table
S1), this proportion was higher in wells containing C cdT+ cells
than in wells containing I cdT+ cells : 1.5 [1.1–2.1], 4.7 [2.6–9.1],
1.4 [1.1–1.8] and 3.9 [2.8–4.0] (% of lymphocytes [IQR])
respectively for I+I, I+C, C+I and C+C.
Intracellular staining for flow cytometry
CD3-CD56-cdT stain (all time points): Following 24 hour of in
vitro stimulation, PBMC were harvested and transferred to FACS
tubes (250,000 cells/tube), washed once in FACS buffer (0.5%
BSA/PBS) and incubated for 15 minutes in 100 ml FACS buffer
with fluorochrome-labelled mAbs against the cell-surface markers
CD3-PerCP (clone CK7, BD Biosciences), TCR Pan c/d-PE
(clone IMMU510, Beckman Coulter, Fullerton, CA, USA) and
CD56-APC (clone MEM188, eBioscience San Diego, CA, USA).
Cells were washed again in FACS buffer and incubated for
15 minutes in 100 ml fixation medium A (Caltag Laboratories,
Carlsbad CA) according to the manufacturer’s instructions,
washed and incubated for 15 minutes with IFNc-FITC (clone
4S.B3, eBioscience) in 100 ml permeabilization medium B. After a
final wash step, cells were re-suspended in FACS buffer and
acquired on a FACScalibur flow cytometer (Becton Dickenson).
Figure S1.A shows the gating strategy for this staining.
Effector memory phenotyping stain (I-1, C-1, C+9, C+35):
Following the procedure described above, cells were stained with
CD45RO-PE (clone UCHL1), CD62L-PE-Cy7 (clone DREG56),
IFNc-FITC (clone 4S.B3) and IL-2-APC (clone MQ1-17H12, all
eBioscience). Figure S1.B shows the gating strategy for this
staining.
Additional T cell phenotyping stain for C+140 and C+400:
Following 24 hour of in vitro stimulation, PBMC were harvested
and transferred to 96 wells V-plate (500,000 cells/well), washed
once in PBS and incubated with 50 ml Live/Dead fixable dead cell
stain kit Aqua (Invitrogen, Carlsbad, CA, USA) in PBS for 30 min
on 4uC. Cells were washed in PBS and for a second time with
FACS buffer (PBS containing 0.5% albumin for bovine serum
(Sigma Chemical Co.)), and stained in 50 ml FACS buffer with
anti-TCR Pan c/d-PE (clone IMMU510, Beckman-Coulter),
CD45RO-ECD (clone UCHL1, Beckman-Coulter), CD3-PerCP
(Clone UCHT1, BioLegend, San Diego, CA, USA), CD62L-PE-
Cy7 (Clone DREG56, eBioscience), CD4-Pacific Blue (Clone
OKT4, eBioscience) and CD8a-Alexa-fluor 700 (clone HIT8a,
BioLegend) for 20 min at 4uC. After washing, cells were incubated
with 50 ml fixation Medium A (Caltag, S. San Francisco, CA,
USA) and subsequently, incubated with anti-IFNc-FITC (clone
4S.B3, eBioscience) and IL-2-APC (Clone MQ1-17H12,
eBioscience) in 50 ml permeabilization Medium B (Caltag) for
20 min at 4uC. Lymphocytes (100,000) gated by forward- and
side-scatter characteristics were acquired on a CyAn ADP 9-color
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flow cytometer (Beckman- Coulter). Figure S1.C and S1.D show
the gating strategy for this staining.
Flow cytometry analysis
Flow cytometry analysis was performed using Cell Quest and
FlowJo V9.1 software. Gating of lymphocytes and subsequent
subgroups was performed as shown in Figure S1. Gating of cells
positive for IFNc and/or IL2 was performed using a cut-off based
on the geometric mean of cells cultured in medium only.
Statistical analysis
Statistical analysis were performed using GraphPad Prism 5.
Differences in responses within volunteers between multiple time
points or between stimuli were analyzed by repeated measures
one-way ANOVA with Dunnett’s or Bonferroni post-hoc test, as
appropriate. Paired/repeated measures analysis was carried out
exclusively on complete data sets obtained within a single
experiment. Two-way analysis with Bonferroni post-test was
performed in order to analyze data sets with multiple variables
(both time points and stimuli). One donor had to be excluded from
all statistical analysis due to an extreme, but highly variable,
outlying IFNc response to PfRBC at time point C+35. All
statistical analyses were performed on data corrected for
background: background responses were subtracted from the
responses to parasite stimuli for every volunteer at every time point
individually (PfRBC - uRBC; sporozoite – mosquito salivary
gland; parasite antigens – medium only); negative values were set
to zero. P-values ,0.05 were considered statistically significant in
all analyses.
Supporting Information
Figure S1 Representative flow cytometry plots. A. CD3-
CD56-cdT stain (all time points). Following 24-hour in vitro
stimulation, live PBMC were gated based on CD3 expression and
sub-populations subsequently further gated based on cdT and
CD56 expression. B. Effector memory phenotyping stain (I-1, C-
1, C+9, C+35). Following 24-hour in vitro stimulation, lymphocytes
were gated based on their forward-sideward scatter and further
gated based on CD45RO/CD62L expression. C. Additional T
cell phenotyping stain for C+140 and C+400. Following 24-hour in
vitro stimulation, only viable single cells were gated. Lymphocytes
were gated based on their forward-sideward scatter and further
sub-gated by CD3 and subsequently CD8/CD4 expression or cd-
TCR expression. To allow comparison with staining B,
CD45RO/CD62L cells were assessed without preceding CD3
gating. D. Intracellular IFNc expression of T-cells, CD4 T-cells
and CD8 T cells following incubation with PfRBC (column 1),
uRBC (column 2), PfSpz (column 3) and MSG (column 4) in
lymphocytes obtained from a volunteer post-challenge.
(TIF)
Figure S2 IFNc responses by different lymphocyte
subsets following in vitro stimulation with PfRBC. PBMC
were isolated from volunteers prior to immunization (day I-1),
immediately prior to patent challenge (day C-1), during expected
blood-stage malaria infection (day C+9), two weeks after treatment
(day C+35), 4.5 months post-challenge (day C+140) and again 1.1
year post-challenge (day C+400). Cells were stimulated in vitro for
24 hours with PfRBC or controls, then stained for phenotype and
intracellular IFNc and analyzed by flow cytometry (gating strategy
illustrated in Figure S1). Shown are the percentage of abT cells
(A - CD3+cd-CD56-), cdT cells (B - CD3+cd+CD56-), NK cells (C
- CD3-cd-CD56+), abNKT cells (D - CD3+cd-CD56+) and
‘cdNKT’ cells (E - CD3+cd+CD56+) staining positive for IFNc
at each time point for volunteers of Group A (left panels) and
Group B (right panels). Background responses were subtracted
from the responses to PfRBC for every individual volunteer at
every individual time point. Symbols represents responses by
individual Group A volunteers (left, n = 10) and Group B
volunteers (right, n = 5) for whom sufficient cells were available.
Horizontal lines represent group medians.
(TIF)
Figure S3 Contribution of CD4+ and CD8+ cells to the
total T lymphocyte IFNc response to PfRBC and PfSpz.
PBMC isolated from volunteers at C+400 were stimulated in vitro
for 24 hours with PfRBC or PfSpz and stained for CD3, CD4 and
CD8 (see Figure S1C). Data represent median values from
Group A and Group B volunteers. Donors with insufficient
numbers of IFNc responding cells to assess the relative
contribution of cell subsets were excluded from composition
analysis. Numbers of donors included are indicated in each box.
(TIF)
Figure S4 Total IL-2 and polyfunctional responses by
EM cells to PfRBC and PfSpz. PBMC of volunteers of Group
A and Group B were stimulated in vitro for 24 hours with PfRBC
or PfSpz or their respective uRBC or MSG controls, then stained
for intracellular IFNc and IL-2 and analyzed by flow cytometry.
Shown are the percentages of effector memory (EM) cells staining
positive for IL-2 (A) or both IFNc and IL-2 (B) at each time point.
Gating strategies are shown in Figure S1. Background responses
were subtracted from the responses to parasite stimuli for every
individual volunteer at every individual time point. Symbols
represents responses by individual Group A volunteers and Group
B volunteers for whom sufficient cells were available. Horizontal
lines represent group medians and IQR.
(TIF)
Figure S5 Contribution of polyfunctional EM cells to
total IFNc and/or IL-2 producing EM cells. PBMC of
volunteers of Group A (A+C) and Group B (B+D) were stimulated
in vitro for 24 hours with PfRBC (A+B) or PfSpz (C+D) or their
respective uRBC or MSG controls, then stained for intracellular
IFNc and IL-2 and analyzed by flow cytometry. Shown are
percentage contributions of polyfunctional (IFNc and IL-2) cells to
the total number of IFNc and/or IL-2 producing effector memory
(EM) cells at each time point, after correction for background for
every individual donor. Gating strategies are shown in Figure S1.
Symbols represents individual Group A volunteers (n = 10) and
Group B volunteers (n = 5) for whom sufficient cells were available.
Horizontal lines represent group medians and IQR.
(TIF)
Figure S6 IFNc responses by PBMC following in vitro
stimulation with cryopreserved or fresh PfRBC. A-F.
PBMC were stimulated for 20 hours in vitro in the presence of
5x106/ml either freshly isolated or cryopreserved PfRBC from the
same batch, equivalent numbers of uRBC, 10 mg/ml PHA or
RPMI only. The collected supernatant was stored at -80uC until
subsequent cytokine measurement. IL-1b (A), IL-2 (B), IL-10 (C),
IL-12p70 (D), IFNc (E) and TNFa (F) secretion into the
supernatant was detected by commercially available microbead
array according to the manufacturer’s instructions (Bio-Rad,
Veenendaal, The Netherlands). Data represent mean+SEM for
five donors.
(TIF)
Table S1 Lymphocyte subset composition in volunteers
prior to, during and post infection.
(RTF)
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Table S2 Parasitemia in volunteers following immuni-
zations and challenge, determined by PCR.
(RTF)
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